Takeda Pharmaceutical Company Limited TKPHF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.69% | -0.26% | -0.54% | -1.29% | -2.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.69% | -0.26% | -0.54% | -1.29% | -2.14% |
| Cost of Revenue | 0.82% | 1.17% | 4.01% | -1.77% | 1.04% |
| Gross Profit | 0.62% | -1.03% | -2.91% | -1.04% | -3.78% |
| SG&A Expenses | -0.07% | -1.08% | -0.92% | 0.47% | -0.89% |
| Depreciation & Amortization | -21.86% | -16.11% | -9.49% | -3.17% | 75.32% |
| Other Operating Expenses | -72.67% | 187.78% | 20.45% | 35.94% | 568.17% |
| Total Operating Expenses | -5.43% | -1.29% | -1.06% | -0.84% | 9.57% |
| Operating Income | 53.76% | 7.16% | 3.23% | -4.30% | -49.24% |
| Income Before Tax | -104.18% | -162.25% | -169.40% | -8.75% | -60.38% |
| Income Tax Expenses | -162.25% | -36.77% | -77.94% | 275.59% | 389.12% |
| Earnings from Continuing Operations | -5.64% | -208.68% | -225.72% | -43.13% | -86.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -10.67% | -40.03% | -23.30% | -43.34% | -24.35% |
| Net Income | -5.73% | -209.03% | -226.21% | -43.21% | -86.54% |
| EBIT | 53.76% | 7.16% | 3.23% | -4.30% | -49.24% |
| EBITDA | 13.52% | -2.43% | -0.98% | -2.66% | -29.21% |
| EPS Basic | -12.68% | -208.13% | -224.36% | -42.60% | -86.16% |
| Normalized Basic EPS | 73.13% | 10.20% | 3.89% | 6.96% | -58.09% |
| EPS Diluted | -24.36% | -213.12% | -231.04% | -43.64% | -86.70% |
| Normalized Diluted EPS | 71.84% | 10.64% | 4.27% | 7.35% | -58.08% |
| Average Basic Shares Outstanding | 0.39% | 0.03% | -0.28% | -0.04% | 0.32% |
| Average Diluted Shares Outstanding | 1.24% | 0.05% | -0.22% | 0.01% | -0.06% |
| Dividend Per Share | -3.24% | 1.00% | 1.00% | 2.22% | 2.22% |
| Payout Ratio | 0.03% | -1.89% | -1.84% | 0.88% | 6.95% |